Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Dexpramipexole

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Areteia Therapeutics Announces Additional $75MM in Series A Financing
    Areteia Therapeutics Announces Additional $75MM in Series A Financing

    13 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240213672000/en

    BUSINESSWIRE
    13 Feb 2024
    Share Share
    Areteia Therapeutics Announces Publication of PII Data of Oral Dexpramipexole
    Areteia Therapeutics Announces Publication of PII Data of Oral Dexpramipexole

    03 Aug 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230803161391/en

    BUSINESSWIRE
    03 Aug 2023
    Share Share
    Areteia Announces Start of Phase III Trials of Oral Dexpramipexole
    Areteia Announces Start of Phase III Trials of Oral Dexpramipexole

    09 Mar 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230309005048/en

    BUSINESSWIRE
    09 Mar 2023
    Share Share
    Bain leads $350M bet on oral asthma startup to fund phase 3
    Bain leads $350M bet on oral asthma startup to fund phase 3

    12 Jul 2022

    // Nick Paul Taylor FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/bain-goes-big-again-leading-350m-round-fund-oral-challenger-blockbuster-asthma-biologics

    Nick Paul Taylor FIERCEBIOTECH
    12 Jul 2022
    Share Share
    Knopp Bio Presents New Phase 2 Data at AAAAI 2022 on Oral Dexpramipexole
    Knopp Bio Presents New Phase 2 Data at AAAAI 2022 on Oral Dexpramipexole

    28 Feb 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220228005167/en

    BUSINESSWIRE
    28 Feb 2022
    Share Share
    Knopp Biosciences Announces Positive Results from the Phase 2 EXHALE Trial
    Knopp Biosciences Announces Positive Results from the Phase 2 EXHALE Trial

    08 Sep 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210114005054/en/Knopp-Biosciences-Announces-Positive-Top-Line-Results-from-the-Phase-2-EXHALE-Trial-of-Oral-Dexpramipexole-in-Moderate-to-Severe-Eosinophilic-Asthma

    BUSINESSWIRE
    08 Sep 2021
    Share Share